Corcept Therapeutics Incorporated (NASDAQ: CORT) is one of the growth stocks that could double by 2027. On July 14, CORT ...

Corcept revised its full-year 2025 revenue guidance to $850-900 million, with the midpoint of $875 million falling below the consensus estimate of $899 million. The company’s stock declined following ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are ...

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer July 14, 2025 — 01:03 pm EDT Written by RTTNews.com for RTTNews -> ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Provided by Business Wire Jul 14, 2025, 5:00:00 AM ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer.

By Colin Kellaher Corcept Therapeutics has filed for U.S. Food and Drug Administration approval of its relacorilant drug candidate for the treatment of patients with platinum-resistant ovarian cancer.